The clinical features of B cell lymphoblastic lymphoma and outcomes after BFM-90 regimen therapy

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 27; no. 10; p. 649
• Main Authors: Sun, Xiao-fei, Zhen, Zi-jun, Xia, Yi, Yang, Qun-ying, Wang, Zhi-hui, Ling, Jia-yu
• Format: Journal Article
• Language: Chinese
• Published: China 01.10.2006
• Subjects: Adolescent; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Child; Child, Preschool; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell - drug therapy; Male; Mercaptopurine - administration & dosage; Methotrexate - administration & dosage; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Treatment Outcome
• ISSN: 0253-2727

To analyse the clinical features of patients with B cell lymphoblastic lymphoma(BCLL) and the outcomes after modified BFM-90 protocol therapy. The clinical features of 14 patients with BCLL were analysed, and compared with that of T cell lymphoblastic lymphoma in the same period. The efficacy and toxicity of modified BFM-90 protocol were analysed. The 14 patients were aged 3 to 18 and diagnosed as BCLL by morphology and immunohistology. One case was in stage I , 2 stage III and 11 stage IV. Most common involved sites were lymph nodes (70% ), skin (50% ) and bone marrow (64% ). One patient received CHOP + HD-MTX, and 13 received modified BFM-90 protocol chemotherapy. Twelve patients (92.3%) achieved complete remission( CR) , 1 patient(7. 7% ) partial remission( PR). The median follow-up duration was 19. 5 months (2 to 44 months). At present 13 patients are alive except one PR patient who gave up treatment and died of disease. The major toxicity of the protocol was myelosuppression, but could be tolerated. The